[go: up one dir, main page]

MX2010006108A - Inhibidores de estearoil-coa-desaturasa. - Google Patents

Inhibidores de estearoil-coa-desaturasa.

Info

Publication number
MX2010006108A
MX2010006108A MX2010006108A MX2010006108A MX2010006108A MX 2010006108 A MX2010006108 A MX 2010006108A MX 2010006108 A MX2010006108 A MX 2010006108A MX 2010006108 A MX2010006108 A MX 2010006108A MX 2010006108 A MX2010006108 A MX 2010006108A
Authority
MX
Mexico
Prior art keywords
stearoyl
inhibitors
coa desaturase
compounds
obesity
Prior art date
Application number
MX2010006108A
Other languages
English (en)
Inventor
Shawn David Erickson
Paul Gillespie
Robert Alan Goodnow Jr
Richard Jones
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010006108A publication Critical patent/MX2010006108A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan aquí compuestos de la fórmula (I): (ver fórmula (I)) así como sales farmacéuticamente aceptables de los mismos, en la que los sustituyentes tienen los significados definidos en la descripción. Estos compuestos y las composiciones farmacéuticas que los contienen son útiles para el tratamiento de enfermedades tales como la obesidad.
MX2010006108A 2007-12-11 2008-12-02 Inhibidores de estearoil-coa-desaturasa. MX2010006108A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US715407P 2007-12-11 2007-12-11
US9002508P 2008-08-19 2008-08-19
PCT/EP2008/066592 WO2009074487A1 (en) 2007-12-11 2008-12-02 Inhibitors of stearoyl-coa desaturase

Publications (1)

Publication Number Publication Date
MX2010006108A true MX2010006108A (es) 2010-06-25

Family

ID=40445593

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006108A MX2010006108A (es) 2007-12-11 2008-12-02 Inhibidores de estearoil-coa-desaturasa.

Country Status (16)

Country Link
US (1) US7652013B2 (es)
EP (1) EP2231619B1 (es)
JP (1) JP5253514B2 (es)
KR (1) KR101198582B1 (es)
CN (1) CN101896473B (es)
AR (1) AR069607A1 (es)
AU (1) AU2008334705B2 (es)
BR (1) BRPI0820972A2 (es)
CA (1) CA2707105C (es)
CL (1) CL2008003659A1 (es)
ES (1) ES2528471T3 (es)
IL (1) IL205505A (es)
MX (1) MX2010006108A (es)
PE (1) PE20091450A1 (es)
TW (1) TW200927744A (es)
WO (1) WO2009074487A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014004426A (es) 2011-10-15 2014-07-09 Genentech Inc Metodos de uso de antagonistas de scd1.
WO2013187069A1 (ja) * 2012-06-15 2013-12-19 国立大学法人金沢大学 Ｐｄｔ効果増強剤
EP3291817B1 (en) * 2015-05-05 2019-10-02 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
GB201617758D0 (en) 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
JP2019533022A (ja) 2016-10-24 2019-11-14 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
CA3049010A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
MX2020009942A (es) 2018-03-23 2021-01-08 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof
HUE064493T2 (hu) 2019-06-10 2024-03-28 Lupin Ltd PRMT5 inhibitorok
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670508A (en) * 1995-10-25 1997-09-23 National Science Council 2-amino-6-alkyl-5-(4-substituted-1-piperazinyl) pyrimidin-4-ones, the preparation and use thereof
DE19929351A1 (de) * 1999-06-26 2000-12-28 Bayer Ag Verfahren zur Herstellung von 4-Chlor-6-hydroxypyrimidin
US20040254359A1 (en) 2001-07-30 2004-12-16 Crooke Rosanne M. Antisense modulation of stearoyl-coa desaturase expression
US7132529B2 (en) 2001-07-30 2006-11-07 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
US20050043256A1 (en) 2001-07-30 2005-02-24 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
PL1648874T3 (pl) * 2003-07-30 2012-04-30 Xenon Pharmaceuticals Inc Pochodne piperazyny i ich zastosowanie jako środków leczniczych
KR100774621B1 (ko) 2003-09-09 2007-11-14 에프. 호프만-라 로슈 아게 정신병 치료용의 글라이신 섭취 억제제로서의1-벤조일-피페라진 유도체
SE0401968D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
US7958010B2 (en) 2005-06-08 2011-06-07 Ian Tzeung Huang Internet search engine with critic ratings
JP2008545760A (ja) * 2005-06-09 2008-12-18 メルク フロスト カナダ リミテツド ステアロイル−コエンザイムａデルタ−９デサチュラーゼのインヒビターとしてのアザシクロヘキサン誘導体

Also Published As

Publication number Publication date
CN101896473B (zh) 2012-07-25
AU2008334705A1 (en) 2009-06-18
JP5253514B2 (ja) 2013-07-31
JP2011506377A (ja) 2011-03-03
US7652013B2 (en) 2010-01-26
CL2008003659A1 (es) 2009-09-04
PE20091450A1 (es) 2009-09-23
CN101896473A (zh) 2010-11-24
EP2231619B1 (en) 2014-11-26
EP2231619A1 (en) 2010-09-29
KR101198582B1 (ko) 2012-11-06
AU2008334705B2 (en) 2011-06-16
BRPI0820972A2 (pt) 2018-08-14
TW200927744A (en) 2009-07-01
AR069607A1 (es) 2010-02-03
CA2707105C (en) 2013-02-12
IL205505A0 (en) 2010-12-30
KR20100082370A (ko) 2010-07-16
IL205505A (en) 2014-01-30
CA2707105A1 (en) 2009-06-18
WO2009074487A1 (en) 2009-06-18
US20090149466A1 (en) 2009-06-11
ES2528471T3 (es) 2015-02-10

Similar Documents

Publication Publication Date Title
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
IL260127B (en) mek inhibitors and methods of using them
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
MY149622A (en) Pyrazoles as 11-beta-hsd-1
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
IN2012DN01233A (es)
MX2010005187A (es) Derivados de 1,2,3-triazol para uso como inhibidores de estearoil-coenzima a desaturasa.
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
TW200806311A (en) Neuropeptide-2 receptor-agonists
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
TW200833663A (en) Therapeutic agents
TW200643013A (en) Pyrazoles
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
IN2012DN03182A (es)
MX2012004089A (es) Inhibidores de hsp90.
MX2009013501A (es) Compuestos piperidinicos y sus usos.
WO2008074824A3 (en) Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase (scd)
UA99787C2 (en) Lactams as beta secretase inhibitors
TW200639156A (en) New compounds
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
IN2012DN03042A (es)
TN2010000038A1 (en) Organic compounds
MX2010002667A (es) Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.

Legal Events

Date Code Title Description
FG Grant or registration